Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma
Advanced Science · 2026-08 · 13 (45)
DOI: 10.1002/advs.202523088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 19.06.2026. Verfasst von Jiawei Zhou und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Children's Hospital Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Sarcoma, Epigenesis, Genetic, Oncogene Addiction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Despite considerable pathological diversity, pediatric sarcomas lack molecularly targeted treatments, demanding deeper pathobiological insights and innovative therapeutic strategies. Here, we demonstrate that overexpressed MDM2 functions as an important pathogenic driver in these malignancies, rewiring oncogenic programs through both p53‐independent chromatin occupancy to regulate active transcription and conventional proteasome‐mediated p53 degradation leading to pathway suppression. To leverage this dependency for targeted eradication of pediatric sarcomas with MDM2 overexpression, we develop MDM2‐recruiting proteolysis‐targeting chimeras that selectively degrade the CDK9/Cyclin T complex (P‐TEFb). Among the lead compounds, dCDK9‐010 demonstrates superior activity compared to its parental CDK9 inhibitor or MDM2 antagonist either alone or in combination, by coordinatedly disrupting the MDM2‐p53 axis and super‐enhancer‐driven transcription. Remarkably, the transcriptional effects of P‐TEFb degradation by dCDK9‐010 are phenocopied by MDM2‐mediated BET degradation, resulting in potent anti‐sarcoma efficacy alongside a favorable therapeutic index and minimal toxicity in nonmalignant cells. Moreover, these MDM2‐recruiting transcriptional/epigenetic machinery degraders (termed MDM2‐TEMADs) consistently impair the homologous recombination repair pathway and confer synthetic lethality with PARP inhibitors. Together, this work elucidates MDM2's central role in pediatric sarcoma pathogenesis and presents dCDK9‐010 as a first‐in‐class, MDM2‐recruiting P‐TEFb degrader and an exemplary MDM2‐TEMAD that enables precise targeting of MDM2‐dependent oncogenic transcriptional addiction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Children's Hospital Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Biochemistry, College of Life Sciences, Zhejiang University, Hangzhou, China.
- Pediatric Cancer Research Center, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medi…
- Department of Orthopedic Surgery, Children's Hospital Zhejiang University School of Medicine, Hangzhou, China.
- Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Jiawei Zhou, Liang Xu
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Innovative Development of Hangzhou Chengxi Science and Technology Innovation Corridor
- Medical Interdisciplinary Innovation Program 2024
Zitieren
APA
Zhou, J., Guan, X., Li, N., Zhang, Y., Xie, L., Huang, X., Zhu, Z., Ren, Z., Yu, X., Guo, H., Wu, Y., Ma, L., Zheng, S., Zhang, J., Liu, J., Lee, V. K., Chen, W., Koeffler, H. P., Wang, J., …, & Xu, L. (2026). Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma. Advanced Science, 13(45). https://doi.org/10.1002/advs.202523088
Vancouver
Zhou J, Guan X, Li N, Zhang Y, Xie L, Huang X, et al. Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma. Advanced Science. 2026;13(45). doi:10.1002/advs.202523088
BibTeX
@article{Zhou2026,
author = {Zhou, Jiawei and Guan, Xian and Li, Nan and Zhang, Ying and Xie, Long and Huang, Xingze and Zhu, Zhipeng and Ren, Zhuolin and Yu, Xiaoyan and Guo, Hanjun and Wu, Yuanfang and Ma, Lin and Zheng, Suya and Zhang, Jingyao and Liu, Jiyang and Lee, Victor Kuanmin and Chen, Wenhao and Koeffler, H Phillip and Wang, Jinhu and Han, Xin and Chen, Ye and Xu, Liang},
title = {Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {45},
doi = {10.1002/advs.202523088}
}
EUVIMED